Beat­ing Mer­ck, Pfiz­er gets pri­or­i­ty re­view as the first Pre­vnar fol­low-up heads to the FDA

It won’t get quite the work-on-Thanks­giv­ing wel­come that the Covid-19 jab re­ceived, but an­oth­er Pfiz­er vac­cine is head­ed to the FDA, where it will re­ceive a speedy re­view.

Pfiz­er an­nounced Wednes­day that an ap­pli­ca­tion for its new pneu­mo­coc­cal vac­cine, 20vP­nC, has been ac­cept­ed and grant­ed pri­or­i­ty re­view at the agency, set­ting up a de­ci­sion by June of next year.

With the ac­cep­tance, Pfiz­er re­mains a step ahead of Mer­ck in the race to de­vel­op a fol­low-on to one of the Big Phar­ma’s most im­por­tant prof­it gen­er­a­tors. While most vac­cines are slim mar­gin prod­uct, Pre­vnar col­lect­ed $6 bil­lion in rev­enue last year, more than any oth­er ful­ly owned Pfiz­er prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER